Phase 1/2Terminated
A Study of Duvelisib in Combination With Pembrolizumab in Head and Neck Cancer
A Phase 1b/2 Study of Duvelisib in Combination With Pembrolizumab in Subjects With Recurrent or Metastatic Head and Neck Squamous Cell Cancer
- Sponsor
- SecuraBio (Industry)
- Enrollment
- 2 enrolled
- Conditions
- Head and Neck Squamous Cell Carcinoma
- Interventions
- Duvelisib; Pembrolizumab
- Ages
- adults, older adults
- Registry
- NCT04193293
Full record on ClinicalTrials.gov
From the registry
This study was designed to assess the safety and preliminary efficacy of duvelisib in combination with pembrolizumab in participants with recurrent or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC).
Primary outcomes
- Stage 1: Number of Participants With Dose-limiting Toxicities
- Stage 1: Number of Participants With Treatment-emergent Adverse Events (TEAEs)
- Stage 1 and 2: Overall Response Rate (ORR)
History
Last registry update
Results first posted
Primary completion
Started
Registered